Spectral Medical Inc.

spectral is a phase iii company seeking u.s. fda approval for its lead theranostics product for the treatment of endotoxemic septic shock. pmx is a therapeutic hemoperfusion device that removes endotoxin, a main trigger of sepsis, from the bloodstream. directed by the company's endotoxin activity assay (eaa™), the only fda cleared diagnostic for the risk of developing sepsis, spectral's euphrates trial is the world's only active and most innovative phase iii study in the area of septic shock. pmx has been approved for therapeutic use in japan and europe, and has been used safely and effectively on more than 100,000 patients to date. in march 2009, spectral obtained the exclusive development and commercial rights in the u.s. for pmx, and in november 2010, signed an exclusive distribution agreement for this product in canada. approximately 350,000 patients are diagnosed with septic shock in north america each year, representing a greater than $3 billion market opportunity for spectral. s